The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals

Danielle M Dunlea, Laura T Fee, Thomas McEnery, Noel G McElvaney, Emer P Reeves Irish Centre for Genetic Lung Disease, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland Abstract: Alpha-1 antitrypsin (AAT) is the most abundant serine protease inhibitor c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dunlea DM, Fee LT, McEnery T, McElvaney NG, Reeves EP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Neutrophils alpha-1 antitrypsin deficiency alpha-1 antitrypsin augmentation inflammation airways disease Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/f1620ab2eb794c16b3c4e4484422dd48
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f1620ab2eb794c16b3c4e4484422dd48
record_format	dspace
spelling	oai:doaj.org-article:f1620ab2eb794c16b3c4e4484422dd482021-12-02T04:53:09ZThe impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals1178-7031https://doaj.org/article/f1620ab2eb794c16b3c4e4484422dd482018-03-01T00:00:00Zhttps://www.dovepress.com/the-impact-of-alpha-1-antitrypsin-augmentation-therapy-on-neutrophil-d-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Danielle M Dunlea, Laura T Fee, Thomas McEnery, Noel G McElvaney, Emer P Reeves Irish Centre for Genetic Lung Disease, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland Abstract: Alpha-1 antitrypsin (AAT) is the most abundant serine protease inhibitor circulating in the blood. AAT deficiency (AATD) is an autosomal codominant condition affecting an estimated 3.4 million individuals worldwide. The clinical disease associated with AATD can present in a number of ways including COPD, liver disease, panniculitis and antineutrophil cytoplasmic antibody vasculitis. AATD is the only proven genetic risk factor for the development of COPD, and deficient individuals who smoke are disposed to more aggressive disease. Principally, AAT is a serine protease inhibitor; however, over the past number of years, the assessment of AAT as simply an antiprotease has evolved, and it is now recognized that AAT has significant anti-inflammatory properties affecting a wide range of cells, including the circulating neutrophil. Keywords: neutrophils, alpha-1 antitrypsin deficiency, alpha-1 antitrypsin augmentation, inflammation, airways diseaseDunlea DMFee LTMcEnery TMcElvaney NGReeves EPDove Medical PressarticleNeutrophilsalpha-1 antitrypsin deficiencyalpha-1 antitrypsin augmentationinflammationairways diseasePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 11, Pp 123-134 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neutrophils alpha-1 antitrypsin deficiency alpha-1 antitrypsin augmentation inflammation airways disease Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	Neutrophils alpha-1 antitrypsin deficiency alpha-1 antitrypsin augmentation inflammation airways disease Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Dunlea DM Fee LT McEnery T McElvaney NG Reeves EP The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
description	Danielle M Dunlea, Laura T Fee, Thomas McEnery, Noel G McElvaney, Emer P Reeves Irish Centre for Genetic Lung Disease, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland Abstract: Alpha-1 antitrypsin (AAT) is the most abundant serine protease inhibitor circulating in the blood. AAT deficiency (AATD) is an autosomal codominant condition affecting an estimated 3.4 million individuals worldwide. The clinical disease associated with AATD can present in a number of ways including COPD, liver disease, panniculitis and antineutrophil cytoplasmic antibody vasculitis. AATD is the only proven genetic risk factor for the development of COPD, and deficient individuals who smoke are disposed to more aggressive disease. Principally, AAT is a serine protease inhibitor; however, over the past number of years, the assessment of AAT as simply an antiprotease has evolved, and it is now recognized that AAT has significant anti-inflammatory properties affecting a wide range of cells, including the circulating neutrophil. Keywords: neutrophils, alpha-1 antitrypsin deficiency, alpha-1 antitrypsin augmentation, inflammation, airways disease
format	article
author	Dunlea DM Fee LT McEnery T McElvaney NG Reeves EP
author_facet	Dunlea DM Fee LT McEnery T McElvaney NG Reeves EP
author_sort	Dunlea DM
title	The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
title_short	The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
title_full	The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
title_fullStr	The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
title_full_unstemmed	The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
title_sort	impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/f1620ab2eb794c16b3c4e4484422dd48
work_keys_str_mv	AT dunleadm theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT feelt theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT mceneryt theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT mcelvaneyng theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT reevesep theimpactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT dunleadm impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT feelt impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT mceneryt impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT mcelvaneyng impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals AT reevesep impactofalpha1antitrypsinaugmentationtherapyonneutrophildrivenrespiratorydiseaseindeficientindividuals
_version_	1718401045393047552

The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals

Ejemplares similares